EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Articles|February 1, 2007
Folliculitis
Author(s)Noah S. Scheinfeld, MD, JD
Folliculitis, which features vesicles filled with white blood cells (pustules), usually affects hair-bearing sites, such as the scalp, neck, beard area, axillae, buttocks, and limbs.
Advertisement
Folliculitis, which features vesicles filled with white blood cells (pustules) (A), usually affects hair-bearing sites, such as the scalp, neck, beard area (B), axillae, buttocks, and limbs.
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
5